H.R. 4278 · 117th Congress
To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.
- Stage
- In committee
- Sponsor
- Gregory Murphy
- Introduced
- 2021-06-30
- Latest action
- 2021-07-01 · Referred to the Subcommittee on Health.
Summary
This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.